Lp(a) Lowering Study of Pelacarsen (TQJ230) in Patients in the US With Elevated Lp(a) and Recent ACS (STEMI/NSTEMI) - Lp(a)FRONTIERS PEARL (clinicaltrials.gov) - Oct 15, 2026 - P3 | N=0 | Withdrawn | Sponsor: Novartis Pharmaceuticals | N=240 ➔ 0 | Not yet recruiting ➔ Withdrawn
Enrollment change • Trial withdrawal • Acute Coronary Syndrome • Cardiovascular
|